STUDY TITLE
A Phase IIb, open label, sequential cohort study comparing KappaMab alone to KappaMab in combination with lenalidomide and low dose dexamethasone (MRd) in Relapsed Refractory Multiple Myeloma
STUDY DESIGN
Multicentre, open label, sequential cohort study
CORRELATIVE STUDIES
Blood and bone marrow samples are collected for biomarkers to correlate clinical response, patterns of clonal evolution during therapy and assessment of minimal residual disease (MRd) resistance
TRIAL PRINCIPAL INVESTIGATOR
Professor Andrew Spencer and Associate Professor Jake Shortt
TIME FRAME
2016 – 2019
PARTICIPANTS
Patients with relapsed refractory multiple myeloma (RR MM) who have received 1-3 prior lines of therapy
TOTAL ENROLMENT
Stage 1: 19
Stage 2: 40
STATUS
Stage 1: Closed to recruitment
Stage 2: Closed to recruitment
SITE LOCATIONS
-
Alfred Hospital, VIC